莫西沙星三联疗法根除2型糖尿病患者幽门螺杆菌感染临床观察

Moxifloxacin-based triple therapy for helicobacter pylori eradication in type 2 diabetic patients

将90例伴有胃肠道症状、幽门螺杆菌（Hp）阳性的2型糖尿病患者分为莫西沙星组和对照组，给予Hp根除治疗。结果显示，莫西沙星组较对照组胃肠道症状改善明显、不良反应发生率少、Hp根除率高，均P〈0．05；治疗前两组的平均空腹血糖及餐后2h血糖、糖化血红蛋白比较差异无统计学意义（P〉0．05）；治疗后莫西沙星组3个月的平均空腹血糖、餐后2h血糖、糖化血红蛋白明显优于对照组（P〈0．05）。提示以莫西沙星为基础的三联疗法对根除2型糖尿病患者Hp感染有很好的疗效，并有利于血糖的控制。

Ninety type 2 diabetic patients with positive helicobacter pylori （Hp） and gastrointestinal symptoms who underwent Hp eradication therapy were randomly divided into two groups, patients in trial group received moxifloxacin 400 mg q. d, omeprazole 20 mg b. i. d and metronidazole 400 mg b. i. d; patients in control group received omeprazole 20mg b. i. d, clarithromycin 0. 5 b. i. d and amoxicillin 1.0 b. i. d. The change of gastrointestinal symptoms before and after therapy, the side effect of medications, rate of Hp eradication, blood glucose and HbAlc were compared between two groups. Comparing the control group, the gastrointestinal symptoms in trial group were improved significantly with less side effects and higher rate of Hp eradication （ all P 〈 0. 05）. Before therapy there were no differences in average fasting blood glucose levels, 2-h postprandial blood glucose and HbAlc between two groups. However, after therapy 3-month average fasting blood glucose levels, 2-h postprandial blood glucose and HbAlc in trial group were significant better than those in control group （P 〈 0. 05 ）. The results indicate that type 2 diabetic patients with Hp infection should receive moxifloxacin-based triple therapy as first-line treatment.